{
  "id": 16205420,
  "title": "STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials",
  "url": "https://urgent.news/2026/10/23/stat-novartis-multiple-sclerosis-treatment-cuts-rates-of-relapse-in",
  "topic": "science",
  "section": "Science",
  "published": "2026-10-23T16:47:31.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/10/23/novartis-remibrutinib-multiple-sclerosis-trial-results/"
  },
  "original_language": "en",
  "account": "Novartis announced that its multiple sclerosis drug, remibrutinib, significantly reduced the occurrence of relapses in patients compared to a standard treatment, according to data presented at a recent conference. The drug was found to lower the annualized relapse rate by 35.2% and 31.2% in two Phase 3 studies, indicating that patients would experience a relapse once every 13 years. While this efficacy is not as high as that of Roche's rival drug, fenebrutinib, which demonstrated a more than 50% reduction in relapse rates, Novartis' treatment has an advantage in terms of safety, potentially making it a competitive option in the market.",
  "summary": "An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}